Aravind S Ravi Kumar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1152723/publications.pdf

Version: 2024-02-01

1307594 1474206 9 253 9 7 citations g-index h-index papers 9 9 9 484 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Radiation Dosimetry in 177Lu-PSMA-617 Therapy. Seminars in Nuclear Medicine, 2022, 52, 243-254.	4.6	16
2	Actinium-225 Prostate-specific Membrane Antigen Theranostics: Will \hat{l}_{\pm} Beat \hat{l}^2 ?. European Urology, 2021, 79, 351-352.	1.9	7
3	Prostate-specific membrane antigen PET/computed tomography for staging prostate cancer. Current Opinion in Urology, 2020, 30, 628-634.	1.8	8
4	Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma. Journal of Nuclear Medicine, 2020, 61, 1326-1330.	5.0	22
5	Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2322-2327.	6.4	101
6	The added benefit of contrast-enhanced CT in evaluation of incidental FDG-avid colon lesions. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2244-2244.	6.4	1
7	Mechanistic Insights for Optimizing PSMA Radioligand Therapy. Clinical Cancer Research, 2020, 26, 2774-2776.	7.0	11
8	Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1902-1910.	6.4	37
9	The segmental distribution and clinical significance of colorectal fluorodeoxyglucose uptake incidentally detected on PET-CT. Nuclear Medicine Communications, 2009, 30, 333-337.	1.1	50